
Pharvaris NV
PHVSHealthcare|Biotechnology|Netherlands
$35.02
-0.86 (-2.39%)
Tangible Book
$4.18
Earnings Power
$4.31
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
null,
42.11,
201.48,
436.06,
712.14
],
"ebit_estimate": [
-220.11,
-197.6,
-58.95,
89.43,
335.83
],
"ebitda_estimate": [
-210.78,
-179.86,
-30.54,
210.04,
453.7
],
"net_income_estimate": [
-214.08,
-193.32,
-88.35,
110.46,
343.41
],
"per_share_eps_estimate": [
-2.97,
-2.68,
-1.14,
1.38,
4.39
],
"eps_nri_estimate": [
-2.98,
-2.68,
-1.1,
1.38,
4.39
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
4.67,
1.88,
1.4,
null,
null
],
"pretax_income_estimate": [
-212.96,
-191.46,
-88.64,
96.9,
344
],
"operating_cash_flow_per_share_estimate": [
-2.04,
-1.2,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
-56.85,
-62.63,
-31.59,
null,
null
],
"gross_margin_estimate": [
100,
79,
82.33,
86,
92
],
"operating_cash_flow_estimate": [
-133.47,
-78.29,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
25.32,
7.98
],
"long_term_growth_rate_mean": 29.46,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 28.6,
"future_eps_nri_estimate_growth": 29.46,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 30.75,
"future_ebitda_estimate_growth": 43.4,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 22.56,
"future_pretax_income_estimate_growth": 22.25,
"future_book_value_per_share_estimate_growth": -36.75,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 18.75,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
null,
null,
null,
2.11,
3.79,
6.97,
18.05
],
"ebit_estimate": [
-53.24,
-55.54,
-62.49,
-56.86,
-56.18,
-55.46,
-41.01
],
"ebitda_estimate": [
-51.43,
-53.37,
-55.13,
null,
null,
null,
null
],
"net_income_estimate": [
-51.6,
-53.54,
-56.48,
-54.58,
-53.9,
-53.18,
-38.73
],
"per_share_eps_estimate": [
-0.74,
-0.75,
-0.79,
-0.79,
-0.78,
-0.76,
-0.6
],
"eps_nri_estimate": [
-0.74,
-0.75,
-0.8,
-0.79,
-0.78,
-0.76,
-0.6
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-50.92,
-53.64,
-61.88,
-54.58,
-53.9,
-53.18,
-38.73
],
"operating_cash_flow_per_share_estimate": [
-1.47,
-2.26,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
92,
92
],
"operating_cash_flow_estimate": [
-96.18,
-147.63,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 29.46,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 28.6,
"future_eps_nri_estimate_growth": 29.46,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 30.75,
"future_ebitda_estimate_growth": 43.4,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 22.56,
"future_pretax_income_estimate_growth": 22.25,
"future_book_value_per_share_estimate_growth": -36.75,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 18.75,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}